Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lone Baandrup

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
BMJ Open|January 10, 2014
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocolPelle L Ishøy, Filip K Knop, Brian V Broberg, et al.
Schizophrenia Research|April 10, 2021
The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE studyDavid Fraguas, Covadonga M Díaz-Caneja, Laura Pina-Camacho, et al.
Therapeutic Advances in Psychopharmacology|November 29, 2023
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen AreaGrimur Høgnason Mohr, Carlo Alberto Barcella, Mia Klinten Grand, et al.
Frontiers in Pharmacology|May 20, 2020
Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial ProtocolOlga B Baltzersen, Herbert Y Meltzer, Vibe G Frokjaer, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|February 12, 2025
Indirect effects of the COVID-19 pandemic on healthcare contacts, quality of care, and social disparities across essential healthcare domainsSøren Valgreen Knudsen, Henry Jensen, Jan Mainz, et al.
Frontiers in Human Neuroscience|November 17, 2022
White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosisJesper Ø Rasmussen, Dorte Nordholm, Louise B Glenthøj, et al.
Eclinicalmedicine|July 17, 2023
Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendationHenriette Edemann-Callesen, Henning Keinke Andersen, Anja Ussing, et al.
Eclinicalmedicine|July 17, 2023
Use of melatonin for children and adolescents with chronic insomnia attributable to disorders beyond indication: a systematic review, meta-analysis and clinical recommendationHenriette Edemann-Callesen, Henning Keinke Andersen, Anja Ussing, et al.
Eclinicalmedicine|July 24, 2023
The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessmentMina Nicole Händel, Henning Keinke Andersen, Anja Ussing, et al.
Bjpsych Open|December 12, 2025
Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia studyArsime Demjaha, Daniel Stahl, Celso Arango, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
BMJ Open|January 10, 2014
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocolPelle L Ishøy, Filip K Knop, Brian V Broberg, et al.
Schizophrenia Research|April 10, 2021
The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE studyDavid Fraguas, Covadonga M Díaz-Caneja, Laura Pina-Camacho, et al.
Therapeutic Advances in Psychopharmacology|November 29, 2023
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen AreaGrimur Høgnason Mohr, Carlo Alberto Barcella, Mia Klinten Grand, et al.
Frontiers in Pharmacology|May 20, 2020
Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial ProtocolOlga B Baltzersen, Herbert Y Meltzer, Vibe G Frokjaer, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|February 12, 2025
Indirect effects of the COVID-19 pandemic on healthcare contacts, quality of care, and social disparities across essential healthcare domainsSøren Valgreen Knudsen, Henry Jensen, Jan Mainz, et al.
Frontiers in Human Neuroscience|November 17, 2022
White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosisJesper Ø Rasmussen, Dorte Nordholm, Louise B Glenthøj, et al.
Eclinicalmedicine|July 17, 2023
Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendationHenriette Edemann-Callesen, Henning Keinke Andersen, Anja Ussing, et al.
Eclinicalmedicine|July 17, 2023
Use of melatonin for children and adolescents with chronic insomnia attributable to disorders beyond indication: a systematic review, meta-analysis and clinical recommendationHenriette Edemann-Callesen, Henning Keinke Andersen, Anja Ussing, et al.
Eclinicalmedicine|July 24, 2023
The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessmentMina Nicole Händel, Henning Keinke Andersen, Anja Ussing, et al.
Bjpsych Open|December 12, 2025
Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia studyArsime Demjaha, Daniel Stahl, Celso Arango, et al.
Pageof 10